

10/598,686

=> d his

(FILE 'HOME' ENTERED AT 12:03:38 ON 29 DEC 2009)

FILE 'REGISTRY' ENTERED AT 12:03:50 ON 29 DEC 2009

L1 2111 S C4S-C6N/EA
L2 13444 S C3N2-C6N/EA
L3 3493 S C5N-C6N/EA
L4 STRUCTURE UPLOADED
L5 19048 S L1 OR L2 OR L3
L6 37 S L4 SUB=L5 SAM
L7 815 S L4 SUB=L5 FUL
L8 4 S L1 AND L7
L9 270 S L2 AND L7
L10 541 S L3 AND L7

FILE 'CAPLUS' ENTERED AT 12:16:02 ON 29 DEC 2009

L11 3 S L8
L12 5 S L9
L13 57 S L10

FILE 'REGISTRY' ENTERED AT 12:16:23 ON 29 DEC 2009

L14 STRUCTURE UPLOADED
L15 68 S L14 SUB=L7 FUL
L16 64 S L15 AND CAPLUS/LC
L17 4 S L15 NOT L16


FILE 'CAPLUS' ENTERED AT 12:39:37 ON 29 DEC 2009

L18 7 S L15

=> d ibib abs hitstr total


L18 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:1124035 CAPLUS
 DOCUMENT NUMBER: 145:455007
 TITLE: Preparation of oxadiazazuleneamines as cannabinoid
 receptor ligands.
 INVENTOR(S): Carpino, Philip Albert; Dow, Robert Lee
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 74pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006111849	A1	20061026	WO 2006-IB1021	20060410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM CA 2605479 A1 20061026 CA 2006-2605479 20060410 EP 1874779 A1 20080109 EP 2006-744571 20060410 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR JP 2008536909 T 20080911 JP 2008-507192 20060410 NL 1031627 A1 20061023 NL 2006-1031627 20060419 NL 1031627 C2 20070710 US 20060241100 A1 20061026 US 2006-409458 20060420 PRIORITY APPLN. INFO.: US 2005-673546P P 20050420 WO 2006-IB1021 W 20060410 OTHER SOURCE(S): CASREACT 145:455007; MARPAT 145:455007 GI				




I

- AB Title compds. [I; R1, R2 = (substituted) aryl, heteroaryl; V = O, W = CR31R32, or V = CR31R32, W = NR4; R31, R32, R51, R52, R61, R62, R71 = H, alkyl, haloalkyl; R4 = H, alkyl, haloalkyl, alkoxycarbonyl, aryl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl; R72 = H, alkyl, alkenyl, haloalkyl, etc.], were prepared. Thus, I (R1 = 2-ClC6H4; R2 = 4-ClC6H4; R51, R52, R61, R62, R71 = H; R72 = Me; V = O; W = CH2) (preparation outlined) showed cannabinoid CB1 receptor binding activity of 47 nM.
- IT 913369-13-8P 913369-14-9P 913369-15-0P
 913369-16-1P 913369-17-2P 913369-18-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxadiazazuleneamines as cannabinoid receptor ligands)
- RN 913369-13-8 CAPLUS
- CN Pyrazolo[4,3-c]azepine-5(4H)-carboxylic acid, 8-amino-2-(2-chlorophenyl)-2,6,7,8-tetrahydro-3-[4-(trifluoromethyl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




- RN 913369-14-9 CAPLUS
- CN Propanamide, N-[2-(2-chlorophenyl)-2,4,5,6,7,8-hexahydro-3-[4-(trifluoromethyl)phenyl]pyrazolo[4,3-c]azepin-8-yl]-2-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 913369-15-0 CAPLUS

CN Propanamide, N-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-8-yl]-2-methyl- (CA INDEX NAME)




RN 913369-16-1 CAPLUS

CN Urea, N'-[2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-8-yl]-N,N-diethyl- (CA INDEX NAME)




RN 913369-17-2 CAPLUS

CN Carbamic acid, [2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,4,5,6,7,8-hexahydropyrazolo[4,3-c]azepin-8-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 913369-18-3 CAPLUS

CN Propanamide, N-[2-(2-chlorophenyl)-2,4,5,6,7,8-hexahydro-3-[4-(trifluoromethyl)phenyl]pyrazolo[4,3-c]azepin-8-yl]-2-methyl- (CA INDEX NAME)




IT 1148140-81-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxadiazazuleneamines as cannabinoid receptor ligands)

RN 1148140-81-1 CAPLUS

CN Pyrazolo[4,3-c]azepine-5(4H)-carboxylic acid,
8-amino-2-(2-chlorophenyl)-3-(4-chlorophenyl)-2,6,7,8-tetrahydro-,
1,1-dimethylethyl ester (CA INDEX NAME)



10/598,686

OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1130645 CAPLUS
 DOCUMENT NUMBER: 143:386939
 TITLE: Preparation of heterocyclic azepine derivatives as
 inhibitor of cholesterol ester transfer protein
 INVENTOR(S): Bell, Michael Gregory; Cao, Guoqing; Escribano, Ana
 Maria; Fernandez, Maria Carmen; Mantio, Nathan Bryan;
 Martin de la Nava, Eva Maria; Mateo Herranz, Ana
 Isabel; Mayhugh, Daniel Ray; Wang, Xiaodong
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097805	A1	20051020	WO 2005-US9294	20050317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1732933	A1	20061220	EP 2005-732643	20050317
EP 1732933	B1	20080723		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
AT 402180	T	20080815	AT 2005-732643	20050317
PT 1732933	E	20081020	PT 2005-732643	20050317
ES 2308477	T3	20081201	ES 2005-732643	20050317
ES 2326326	T3	20091007	ES 2005-725968	20050317
ZA 2006006737	A	20080227	ZA 2006-6737	20060814
US 20070208003	A1	20070906	US 2006-598686	20060908
PRIORITY APPLN. INFO.:			US 2004-557134P	P 20040326
			US 2004-621162P	P 20041022
			WO 2005-US9294	W 20050317
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 143:386939; MARPAT 143:386939				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Q = (CH₂)_j; n = 0-3; m = 0-6; j = 1-2; q = 0-2; W, X, Y and Z independently = CH, C, N, etc.; A = 5-6 membered ring wherein one of W, X, Y or Z may be absent with provisions; K = bond, CO or S(O)_p; p = 0-2; R₁ = OH, alkyl, alkenyl, etc.; R₂ = H, halo, alkynyl, etc.; R₃ = H,

aryl, cycloalkyl, etc.; R4 = NR7R8; R5 = H, OH, halo, etc.; R6 = H, alkyl, alkenyl, etc.; R7 = alkyl, alkenyl, cycloalkyl, etc.; R8 = aryl, alkylaryl, alkenylaryl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of cholesterol ester transfer protein (CEPT). Thus, e.g., II was prepared by cyclization of 4-[isopropoxycarbonyl-(3-methoxycarbonyl-propyl)-amino]-thiophene-3-carboxylic acid Me ester (preparation given) using potassium tert-butoxide followed by decarboxylation/amination sequence using 3,5-bis(trifluoromethyl)benzylamine and subsequent acylation using acetic anhydride. The ability of I to inhibit the transfer of radiolabeled cholesterol esters between HDL and LDL was evaluated using an in vitro scintillation proximity assay and it was revealed that compds. of the invention possessed an activity of below 100 μ M. I should prove useful in the treatment of dyslipidemia. Pharmaceutical compns. comprising I are disclosed.


IT	866774-51-8P	866774-57-4P	866774-59-6P
	866774-61-0P	866774-63-2P	866774-65-4P
	866774-67-6P	866774-69-8P	866774-70-1P
	866774-71-2P	866774-72-3P	866774-73-4P
	866774-74-5P	866774-76-7P	866774-77-8P
	866774-78-9P	866774-79-0P	866774-80-3P
	866774-81-4P	866774-82-5P	866774-83-6P
	866774-84-7P	866774-85-8P	866774-86-9P
	866774-87-0P	866774-88-1P	866774-89-2P
	866774-90-5P	866774-91-6P	866774-92-7P
	866774-93-8P	866774-94-9P	866774-95-0P
	866774-96-1P	866774-97-2P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic azepine derivs. as inhibitors of cholesterol ester transfer protein)


RN 866774-51-8 CAPLUS

CN 1H-Thieno[3,4-b]azepine-1-carboxylic acid,
5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2,3,4,5-tetrahydro-
1-methylethyl ester (CA INDEX NAME)




RN 866774-57-4 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-chloro-6,7,8,9-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-59-6 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-
 2-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-61-0 CAPLUS


CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-bromo-6,7,8,9-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-63-2 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2-(dimethylamino)-
 6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-65-4 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-6,7,8,9-tetrahydro-
 2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-67-6 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2-cyano-6,7,8,9-
 tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-69-8 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-3-chloro-6,7,8,9-
 tetrahydro-2-methoxy-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-70-1 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
9-[acetyl(1-methylethyl)amino]-3-chloro-2-ethoxy-
6,7,8,9-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-71-2 CAPLUS


CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
9-[acetyl(1-methylethyl)amino]-6,7,8,9-tetrahydro-
2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866774-72-3 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-
 2-methyl-3-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 866774-73-4 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-
 yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl
 ester (CA INDEX NAME)




RN 866774-74-5 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-,
 1,1-dimethylethyl ester (CA INDEX NAME)




RN 866774-76-7 CAPLUS


CN 9H-Pyrido[2,3-b]azepine-9-carboxylic acid,
 5-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-5,6,7,8-tetrahydro-,
 1-methylethyl ester (CA INDEX NAME)



RN 866774-77-8 CAPLUS
 CN 1H-Pyrido[3,4-b]azepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 , 1-methylethyl ester (CA INDEX NAME)




RN 866774-78-9 CAPLUS
 CN 1H-Pyrido[4,3-b]azepine-1-carboxylic acid,
 5-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-2,3,4,5-tetrahydro-
 , 1-methylethyl ester (CA INDEX NAME)




RN 866774-79-0 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
9-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-6,7,8,9-tetrahydro-
-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-80-3 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
9-[acetyl[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]-6,7,8,9-tetrahydro-
2-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-81-4 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
9-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-
3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 866774-82-5 CAPLUS

CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-
5-(cyclopentylmethyl)-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-
5-yl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 866774-83-6 CAPLUS

CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(cyclopropylmethyl)-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 866774-84-7 CAPLUS

CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(3-pyridinylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 866774-85-8 CAPLUS

CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(4-pyridinylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 866774-86-9 CAPLUS

CN Benzoic acid, 3-[[9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-5-yl]methyl]- (CA INDEX NAME)



RN 866774-87-0 CAPLUS


CN Benzoic acid, 4-[[[9-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-5-yl]methyl]- (CA INDEX NAME)



RN 866774-88-1 CAPLUS


CN 5H-Pyrido[3,2-b]azepine-5-pentanoic acid,
9-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-

yl)amino]-6,7,8,9-tetrahydro- β , β ,2-trimethyl-3-(trifluoromethyl)-
(CA INDEX NAME)




RN 866774-89-2 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[9-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-5-yl]methyl]- (CA INDEX NAME)




RN 866774-90-5 CAPLUS

CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-ethyl-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-3- (CA INDEX NAME)




RN 866774-93-8 CAPLUS

CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(phenylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)




RN 866774-94-9 CAPLUS

CN 5H-Pyrido[3,2-b]azepin-9-amine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6,7,8,9-tetrahydro-2-methyl-N-(2-methyl-2H-tetrazol-5-yl)-5-(2-thiazolylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 866774-95-0 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-,
 tetrahydro-3-furanyl ester (CA INDEX NAME)




RN 866774-96-1 CAPLUS

CN Carbamic acid, [[3,5-bis(trifluoromethyl)phenyl]methyl][6,7,8,9-tetrahydro-2-methyl-5-(4-pyridinylmethyl)-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-


10/598,686

9-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 866774-97-2 CAPLUS

CN Acetamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-[6,7,8,9-tetrahydro-2-methyl-5-(4-pyridinylmethyl)-3-(trifluoromethyl)-5H-pyrido[3,2-b]azepin-9-yl]- (CA INDEX NAME)



IT 1038588-70-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heterocyclic azepine derivs. as inhibitors of cholesterol ester transfer protein)

RN 1038588-70-3 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,

9-[[[3,5-bis(trifluoromethyl)phenyl]methylamino]-6,7,8,9-tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



IT 866775-02-2P 866775-25-9P 866775-26-0P

866775-27-1P 866775-28-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic azepine derivs. as inhibitors of cholesterol ester transfer protein)

RN 866775-02-2 CAPLUS


CN 1H-Thieno[3,4-b]azepine-1-carboxylic acid,

5-[[[3,5-bis(trifluoromethyl)phenyl]methylamino]-2,3,4,5-tetrahydro-, 1-methylethyl ester (CA INDEX NAME)




RN 866775-25-9 CAPLUS

CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-6,7,8,9-tetrahydro-2-
methyl-3-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 866775-26-0 CAPLUS


CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-6,7,8,9-tetrahydro-2-
methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX NAME)



RN 866775-27-1 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-2H-tetrazol-5-ylamino]-6,7,8,9-
 tetrahydro-2-methyl-3-(trifluoromethyl)-, 1-methylethyl ester (CA INDEX
 NAME)



RN 866775-28-2 CAPLUS
 CN 5H-Pyrido[3,2-b]azepine-5-carboxylic acid,
 9-[[[3,5-bis(trifluoromethyl)phenyl]methyl]cyanoamino]-6,7,8,9-tetrahydro-
 2-methyl-3-(trifluoromethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




OS.CITING REF COUNT:	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:2730 CAPLUS
 DOCUMENT NUMBER: 140:71043
 TITLE: Combination treatment for depression and anxiety by
 NK1 and NK3 antagonists
 INVENTOR(S): Sobolov-Jaynes, Susan Beth; Lowe, John Adams, III;
 McLean, Stafford
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000355	A1	20031231	WO 2003-IB2516	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040006135	A1	20040108	US 2003-386582	20030312
CA 2488311	A1	20031231	CA 2003-2488311	20030610
AU 2003239280	A1	20040106	AU 2003-239280	20030610
EP 1517708	A1	20050330	EP 2003-732858	20030610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011898	A	20050412	BR 2003-11898	20030610
JP 2005533080	T	20051104	JP 2004-515136	20030610
MX 2005000260	A	20050411	MX 2005-260	20050103
PRIORITY APPLN. INFO.:			US 2002-389975P	P 20020619
			WO 2003-IB2516	W 20030610
OTHER SOURCE(S):	MARPAT 140:71043			
AB	The invention discloses a method for treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK1 receptor antagonist (e. g., a substance P receptor antagonist) in combination with an NK3 antagonist agent. It also relates to pharmaceutical compns. containing a pharmaceutically acceptable carrier, a CNS-penetrant NK1 receptor antagonist and an NK3 antagonist.			
IT	640277-50-5 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (NK1 and NK3 antagonist combination treatment for depression and anxiety)			
RN	640277-50-5 CAPLUS			
CN	Ethanone, 1-[(2R)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-[6-(phenylmethyl)-6-azabicyclo[3.2.2]non-3-yl]amino]- (CA INDEX NAME)			

Absolute stereochemistry.




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:340180 CAPLUS
 DOCUMENT NUMBER: 137:78847
 TITLE: Rearrangement of a Mesylate Tropane Intermediate in
 Nucleophilic Substitution Reactions. Synthesis of
 Aza-Bicyclo[3.2.1]octane and Aza-Bicyclo[3.2.2]nonane
 Ethers, Imides, and Amines
 AUTHOR(S): Ogier, Lionel; Turpin, Frederic; Baldwin, Ronald M.;
 Riche, Francoise; Law, Ho; Innis, Robert B.; Tamagnan,
 Gilles
 CORPORATE SOURCE: Department of Psychiatry, Yale University and VA CT
 HCS, West Haven, CT, USA
 SOURCE: Journal of Organic Chemistry (2002), 67(11), 3637-3642
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:78847
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Nonracemic mesyloxymethyltropane I undergoes nucleophilic substitution
 reactions with alcohols, amines, and imides to give bicyclononanes II
 (R = H, Me; R1 = MeO, H2C:CHCH2O, 3,4-methylenedioxyphenoxy,
 N-phthalimidiny, H2N, PhCH2NH) and substituted methyltropanses III (R2 =
 N-phthalimidiny, H2N, PhCH2NH). Alcohols give II as the sole
 products; amines and imides give mixts. of II and III. The reactivity of
 I is explained by intramol. neighboring group assistance to give the
 azetidinium mesylate IV; the regioselectivity of ring opening reactions of
 IV is determined by the hardness of the nucleophile. Other tropanses are also
 prepared
 IT 440370-64-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of nonracemic azabicyclo[3.2.2]nonanes and methyltropanses by
 stereoselective nucleophilic substitution reactions of a tropane
 mesylate with alcohols, amines, and imides)
 RN 440370-64-9 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[(1R,2S,5S,8S)-6-methyl-8-(4-methylphenyl)-6-
 azabicyclo[3.2.2]non-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 440370-65-0P 440370-66-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of nonracemic azabicyclo[3.2.2]nonanes and methyltropanes by
 stereoselective nucleophilic substitution reactions of a tropane
 mesylate with alcoholates, amines, and imides)
 RN 440370-65-0 CAPLUS
 CN 6-Azabicyclo[3.2.2]nonan-2-amine, 6-methyl-8-(4-methylphenyl)-,
 (1R,2S,5S,8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 440370-66-1 CAPLUS
 CN 6-Azabicyclo[3.2.2]nonan-2-amine, 6-methyl-8-(4-methylphenyl)-N-
 (phenylmethyl)-, (1R,2S,5S,8S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)

10/598,686

REFERENCE COUNT:


37

THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:670114 CAPLUS
 DOCUMENT NUMBER: 131:286538
 TITLE: Preparation of 1,4-diacyl piperazines and analogs as neurokinin antagonists
 INVENTOR(S): Blythin, David J.; Chen, Xiao; Friary, Richard J.; McCormick, Kevin D.; Piwinski, John J.; Shih, Neng-yang; Shue, Ho-jane
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: U.S., 85 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5968929	A	19991019	US 1997-958896	19971028
US 6051575	A	20000418	US 1999-313150	19990517
PRIORITY APPLN. INFO.:			US 1996-29813P	P 19961030
			US 1997-958896	A3 19971028

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 131:286538
 GI




AB Title compds. [I;R1 = C(:X)(CHRC')lA1; A1 = (un)substituted Ph, -naphthyl, -heteroaryl, etc.; R2 = (CH2)uA2; A2 = (un)substituted Ph, -naphthyl; R3 = [C(:X)]m(CHRC)yR; R = e.g., (di)azabicycloalkylamino having ring-N substituent G; G = H, alkyl, acyl, arylmethyl, etc.; Rc = H, alkyl, (CH2)1-4R4; R4 = ORa, NRaRb, CO2Ra, imidazolyl, etc.; Ra,Rb = H, alkyl, Ph, etc.; Rc' = H, (CH2)nORa; X = O, H2, NH, etc.; Z = (CH2)0-2; u,n,l = 0-2; m = 1 and y = 1-3; m = 2 and y = 0] were prepared. Thus, (R)-1-bromoacetyl-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazine was aminated by 1,1-dimethylethyl 5-amino-2-azabicyclo[2.2]heptane-2-carboxylate (preparation each given) to give title compound II (R2 = 3,4-dichlorophenyl). Data for biol. activity of I were given.

IT 640277-50-5 1099570-38-3 1099570-39-4
 1099570-40-7
 RL: PRPH (Prophetic)
 (Preparation of 1,4-diacyl piperazines and analogs as neurokinin antagonists)

RN 640277-50-5 CAPLUS


CN Ethanone, 1-[(2R)-2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-[[6-(phenylmethyl)-6-azabicyclo[3.2.2]non-3-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1099570-38-3 CAPLUS

CN 6-Azabicyclo[3.2.2]nonane-6-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1099570-39-4 CAPLUS


CN 6-Azabicyclo[3.2.2]nonane-6-carboxylic acid, 3-[[2-[[2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-piperazinyl]-2-oxoethyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



10/598,686

RN 1099570-40-7 CAPLUS

CN Ethanone, 2-(6-azabicyclo[3.2.2]non-3-ylamino)-1-[2-(3,4-dichlorophenyl)-1-piperazinyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1993:551630 CAPLUS
 DOCUMENT NUMBER: 119:151630
 ORIGINAL REFERENCE NO.: 119:26901a,26904a
 TITLE: Substituted benzamides with conformationally restricted side chains. 3. Azabicyclo[x.y.0] derivatives as gastric prokinetic agents
 AUTHOR(S): Hadley, M. S.; King, F. D.; McRitchie, B.; Smith, D. M.; Turner, D. H.
 CORPORATE SOURCE: SmithKline Beecham Pharm., Pinnacles/Harlow/Essex, CM19 5AD, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1992), 2(9), 1147-52
 CODEN: BMCLE8; ISSN: 0960-894X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The effect of alteration of ring size, introduction of alternative substituents and insertion of an exocyclic methylene group on the gastric prokinetic and dopamine antagonist activity of azabicyclic benzamides related to the serotonin 5-HT₄ agonist, BRL 20627 is described.
 IT 149978-20-1 149978-21-2 149978-22-3
 RL: BIOL (Biological study)
 (dpaminergic-antagonist and stomach-stimulating activity of, structure in relation to)
 RN 149978-20-1 CAPLUS
 CN Benzamide, 4-amino-5-chloro-N-(decahydropyrido[1,2-a]azepin-9-yl)-2-methoxy-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 149978-21-2 CAPLUS
 CN Benzamide, 4-amino-5-chloro-N-(decahydropyrido[1,2-a]azepin-9-yl)-2-methoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10/598,686



RN 149978-22-3 CAPLUS

CN Benzamide, 4-amino-5-chloro-N-(decahydropyrido[1,2-a]azepin-8-yl)-2-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L18 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1987:407086 CAPLUS

DOCUMENT NUMBER: 107:7086

ORIGINAL REFERENCE NO.: 107:1307a,1310a

TITLE: Azabicycloalkanes procedure for their preparation, and

their use as pharmaceuticals

INVENTOR(S): King, Francis David; Joiner, Karen Anne

PATENT ASSIGNEE(S): Beecham Group PLC, UK

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1





PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 214772	A1	19870318	EP 1986-306221	19860812
R: BE, CH, DE, FR, GB, IT, LI, NL				
US 4798829	A	19890117	US 1986-896664	19860814
JP 62059278	A	19870314	JP 1986-190676	19860815
PRIORITY APPLN. INFO.:			GB 1985-20616	A 19850816

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 107:7086

GI



AB Azabicycloalkanes I [n = 1-3; m, p = 1, 2; m + n + p ≥ 4; X = NH, O; Ar = (un)substituted Ph, Q [R8, R9 = H, substituents, Z = CH2, O, S, (un) substituted NH, Y = CH, N; Z = CH, N, Y = (un)substituted NH, CH2]; R1, R2, R3 = H, alkyl, Ph, phenylalkyl, Ph(un)substituted by alkyl, alkoxy, halo], having gastric motility enhancing, and/or antiemetic, and/or 5-HT receptor antagonist activity, were prepared by reaction of ArG (G = COQ1; Q1 = leaving group) with II (L = NH2 or OH or a reactive derivative thereof). Oximation of 1-azabicyclo[3.2.2]nonan-4-one gave 75% the oxime-HCl, reduction of which with Na in amyl alc. gave 68% 4-amino-1-azabicyclo[3.2.2]nonane. Acylation with 3,5-Cl2C6H3COCl in CH2Cl2 gave 63% (±)-III. The ED50 of (±)-III to reduce the 5-HT


evoked response in rats was 0.008 mg/kg i.v. (antagonism of the van Bezold-Jarisch reflex from .apprx.6 µg/kg 5-HT).

IT 108551-28-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion to free base)

RN 108551-28-6 CAPLUS

CN 1-Azabicyclo[3.2.2]nonan-4-amine, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

IT 108551-29-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and saponification of)

RN 108551-29-7 CAPLUS

CN Benzamide, 4-(acetyl amino)-N-1-azabicyclo[3.2.2]non-4-yl-5-chloro-2-methoxy- (CA INDEX NAME)




IT 108551-27-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and N-arylation of)

RN 108551-27-5 CAPLUS


CN 1-Azabicyclo[3.2.2]nonan-4-amine (CA INDEX NAME)



IT 108551-32-2P 108551-33-3P 108551-34-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as 5-HT receptor antagonist)
 RN 108551-32-2 CAPLUS
 CN Benzamide, 4-amino-N-1-azabicyclo[3.2.2]non-4-yl-5-chloro-2-methoxy- (CA
 INDEX NAME)




RN 108551-33-3 CAPLUS
 CN Benzamide, N-1-azabicyclo[3.2.2]non-4-yl-3,5-dichloro- (CA INDEX NAME)



RN 108551-34-4 CAPLUS

10/598,686

CN 1H-Indazole-3-carboxamide, N-1-azabicyclo[3.2.2]non-4-yl-1-methyl- (CA
INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

10/598,686

L17 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 301335-12-6 REGISTRY
ED Entered STN: 06 Nov 2000
CN Benzamide, N-[(1S,3R,5R)-6-methyl-6-azabicyclo[3.2.2]non-3-yl]- (CA INDEX
NAME)
FS STEREOSEARCH
MF C16 H22 N2 O
SR CA

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,686

L17 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1027400-70-9 REGISTRY
ED Entered STN: 11 Jun 2008
CN 1-Azabicyclo[3.2.2]nonan-4-amine, 2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-, (2R,4R)- (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H34 N2 O
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,686

L17 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1026691-71-3 REGISTRY
ED Entered STN: 09 Jun 2008
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C17 H26 N4 O2
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,686

L17 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1026582-64-8 REGISTRY
ED Entered STN: 08 Jun 2008
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C20 H30 N2 O2
SR Other Sources
Database: ChemSpider (ChemZoo, Inc.)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT